PR Newswire Clinical TrialsOriginal article
Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation
Positive
AI Analysis
Summary
Inomagen Therapeutics received a NIH SBIR grant of up to $2.9 million to support preclinical development and manufacturing activities for its non-viral gene therapy targeting atrial fibrillation, with the goal of advancing toward an Investigational New Drug application.
Outcome Details
NIH SBIR grant awarded
Importance:3/10
Sentiment:
0.60
gene therapynon-viralNIH fundingSBIR grantatrial fibrillationpreclinicalIND application
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 16, 2026 2:55 PM